ADMA Biologics share price today

ADMA Biologics, Inc.'s share price was $10.48 at the close on 4 November 2026. It has been falling for 1 week. That is 3.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $8 and $20, and at that close it sat 21% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today ADMA Biologics, Inc. is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row.

Over the last 10 years the share price moved +55% while the S&P 500 moved +261%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

ADMA Biologics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

ADMA Biologics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

ADMA Biologics, Inc. earned $37.8 M of net profit in the Jun 2026 quarter, +10.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $147 M. That is 30.4% of the quarter's revenue. The same quarter a year earlier earned $34.2 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

For the full year, FY25 profit was $147 M (−25.7% on the year before).

Why profit moved: revenue changed +2.0% on a year earlier and the margin moved +7.1 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +6.1% and revenue +8.0%. Profit and revenue are moving at about the same pace.

ADMA Biologics, Inc. reported $124 M of revenue in the Jun 2026 quarter, +2.0% on the same quarter a year earlier. Over 4 years it has grown 58.4% a year on average. The last full year, FY25, came in at $510 M. The last four reported quarters add to $512 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $510 M, +19.6% on the year before.

Recent pace: the last four quarters grew +8.0% on average, against 58.4% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +8.0%, against +24.5% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −19.1%, against +120.4% a year (rolling over).

ADMA Biologics, Inc.'s operating margin was 42.2% in the Jun 2026 quarter, 7.1 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −71.1% and 37.5%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between −71.1% and 37.5%, and FY25's 37.5% is the highest of them.

Why the margin moved: operating margin changed +7.1 percentage points on the year while gross margin changed +14.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 2 years, 49% of ADMA Biologics, Inc.'s reported profit came in as cash from its operations, a gap worth watching. In FY25 it brought in $50.4 M of operating cash against $147 M of profit. After $22.6 M of spending on assets, $27.8 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

ADMA Biologics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $35.6 M on assets over the last 3 years. Averaged over those years that is 2.3% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $35.6 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

ADMA Biologics, Inc.'s P/E is 15.0×, near the low end of its own history: it has been lower only 20% of the time. Its usual P/E (the middle reading) is 22.2×, over 2.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

Why the multiple is where it is: over the past year earnings per share moved −25.9% while the price moved −27.8%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

ADMA Biologics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

ADMA Biologics, Inc. earned a ROE of 31% in FY25. That is up from a low of −51% in FY21. Its return on capital used (ROIC) is 28.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 28.8% net margin and 0.82× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 28.8% net margin × 0.82× asset turnover × 1.31× leverage (assets divided by equity) ≈ 30.9% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 36.2% − 7.5% = +28.7 percentage points. The 7.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 36.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 38.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.